ReviewWellcome open research2024
Clinical trials and their impact on policy during COVID-19: a review.
Review in Wellcome open research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- A scoping review of randomized controlled trials in the early phase of the COVID-19 pandemic: country-level research response to COVID-19 therapeutics and vaccines.BMC infectious diseases · 2026Article
- Managing costly new drugs to support equitable access: international collaboration and patient engagement to assess value, and managed entry agreements.BMJ (Clinical research ed.) · 2025Article
- How to build a better clinical trial ecosystem for future infectious disease emergencies in Japan: Findings from a narrative review and stakeholder meetings.Global health & medicine · 2025Review
- Issues regarding the Indexing of Adaptive Clinical Trial Articles.medRxiv : the preprint server for health sciences · 2025Article
- Proposal and Strategy for Nursing-Led Research: Protocol for an Unfunded Clinical Trial.JMIR research protocols · 2025Article
- Article
- Propensity Score Methods for Confounding Control in Observational Studies of Therapeutics for COVID-19 Infection.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2024Article
- Article
- Clinical trials and their impact on policy during COVID-19: a review.Wellcome open research · 2024Review
- Ethical priorities for international collaborative adaptive platform trials for public health emergencies.BMJ global health · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Background: Of over 8,000 recorded randomised trials addressing COVID-19, around 80% were of treatments, and 17% have reported results. Approximately 1% were adaptive or platform trials, with 25 having results available, across 29 journal articles and 10 preprint articles. Methods: We conducted an extensive literature review to address four questions about COVID-19 trials, particularly the role and impact of platform/adaptive trials and lessons learned. Results: The key findings were: Conclusion: There is a need to (i) reduce small, repetitive, single centre trials, (ii) increase coordination to ensure robust research conducted for treatments, and (iii) a wider adoption of adaptive/platform trial designs to respond to fast-evolving evidence landscape.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.